Image Source: AsiaOne
FibroGenesis Reports Breakthrough in Prevention of COVID-19 Blood Clotting Laboratory Studies Suggest PneumoBlast™ COVID-19 Cell Therapy Reduces Coagulopathy GlobeNewswire August 12, 2020 HOUSTON, Aug. 12, 2020 (GLOBE NEWSWIRE) -- FibroGenesis, a clinical stage company developing fibroblast based therapeutic solutions for unmet medical needs, announced today new data supporting utilization of its PneumoBlast™ product in treatment of COVID-19. Laboratory experiments comprised of admixing PneumoBlast™ with activated monocyte or endothelial cells demonstrated significant inhibition of tissue factor expression. Tissue factor is the key molecule inducing blood clotting in COVID-19 patients. Monocytes are cells which normally protect the body against pathogens. In the case of COVID-19, monocytes enter the lungs and cause coagulation. Endothelial cells are cells which make up the inside of the blood vessel and regulate substance flow between the bloodstream and surrounding tissues.
Source: AsiaOne